Vla-4 inhibitors
AssigneeDaiichi Pharmaceutical Co., Ltd.
InventorsAtsushi Nakayama, Nobuo Machinaga, Yoshiyuki Yoneda, Yuichi Sugimoto, Jun Chiba, Toshiyuki Watanabe, Shin Iimura
Life of this patent
Estimating the term…
Loading patent…
AssigneeDaiichi Pharmaceutical Co., Ltd.
InventorsAtsushi Nakayama, Nobuo Machinaga, Yoshiyuki Yoneda, Yuichi Sugimoto, Jun Chiba, Toshiyuki Watanabe, Shin Iimura
Estimating the term…
The present invention relates to a compound represented by the following formula (I): 1 (wherein, W represents WA—A1—WB— (in which, WA is substituted or unsubstituted aryl, etc., A1 is —NR1—, single bond, —C(O)—, etc., and WB is substituted or unsubstituted arylene, etc.), R is single bond, —NH—, —OCH2—, alkenylene, etc., X is —C(O)—, —CH2—, etc., and M is, for example, the following formula: 2 (in which, R11, R12 and R13 each independently represents hydrogen, hydroxyl, amino, halogen, etc., R14 is hydrogen or lower alkyl, Y represents —CH2—O—, etc., Z is substituted or unsubstituted arylene, etc., A2 is single bond, etc, and R10 is hydroxyl or lower alkoxy)), or salt thereof; and a medicament containing the same. This compound or salt thereof selectively inhibits binding of cell adhesion molecules to VAL-4 and exhibits high bioavailability so that it is useful as a preventive and/or remedy for inflammatory diseases, autoimmune diseases, metastasis, bronchial asthma, rhinostenosis, diabetes, and the like.
A compound represented by the following formula (I):
Dependencies are inferred from the claim text.